Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 1, 2013, Pages 209-215

  Osawa, Gakuji ^a   Yoshimatsu, Kazuhiko ^a   Yokomizo, Hajime ^a   Okayama, Sachiyo ^a   Sagawa, Masano ^a   Naritaka, Yoshihiko ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Bevacizumab; Chemotherapy; Colorectal cancer; Computed tomography; Contrast enhancement

Indexed keywords

BEVACIZUMAB; OXALIPLATIN;

ABDOMINAL RADIOGRAPHY; AGED; ARTICLE; CANCER INHIBITION; CANCER LOCALIZATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; IMAGE ANALYSIS; LIVER METASTASIS; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; CONTRAST MEDIA; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84879793148     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2186-x     Document Type: Article

References (37)

1. Benson AB 3rd, Bekaii-Saab T, Chan E et al (2013) Metastatic colon cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 11:141-152
2. Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671
3. Okines A, Puerto OD, Cunningham D et al (2009) Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 101:1033-1038
4. Karapetis CS, Khambata-Ford S, Jonker DJ (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765
5. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
6. Weidner N (1995) Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147:9-19
7. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. Engl J Med 324:1-8
8. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410
9. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368-4380
10. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581-611
11. Masaki T, Ohkawa S, Amano A, Ueno M, Miyakawa K, Tarao K (2005) Noninvasive assessment of tumor vascularity by contrast-enhanced ultrasonography and the prognosis of patients with nonresectable pancreatic carcinoma. Cancer 103:1026-1035
12. Hosten N, Puls R, Lemke AJ et al (1999) Contrast-enhanced power Doppler sonography: improved detection of characteristic flow patterns in focal liver lesions. J Clin Ultrasound 27:107-115
13. Wilson SR, Burns PN, Muradali D, Wilson JA, Lai X (2000) Harmonic hepatic US with microbubble contrast agent: initial experience showing improved characterization of hemangioma, hepatocellular carcinoma, and metastasis. Radiology 215:153-161
14. Ding H, Kudo M, Onda H, Suetomi Y, Minami Y, Maekawa K (2001) Hepatocellular carcinoma: depiction of tumor parenchymal flow with intermittent harmonic power Doppler US during the early arterial phase in dual-display mode. Radiology 220:349-356
15. Ren J, Huan Y, Wang H et al (2008) Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis. Clin Radiol 63:153-159
16. Yabuuchi H, Fukuya T, Tajima T, Hachitanda Y, Tomita K, Koga M (2003) Salivary gland tumors: diagnostic value of gadolinium-enhanced dynamic MR imaging with histopathologic correlation. Radiology 226:345-354
17. Zhang XM, Yu D, Zhang HL et al (2008) 3D dynamic contrast-enhanced MRI of rectal carcinoma at 3T: correlation with microvascular density and vascular endothelial growth factor markers of tumor angiogenesis. J Magn Reson Imaging 27:1309-1316
18. Chen WX, Min PQ, Song B, Xiao BL, Liu Y, Ge YH (2004) Single-level dynamic spiral CT of hepatocellular carcinoma: correlation between imaging features and density of tumor microvessels. World J Gastroenterol 10:67-72
19. Hattori Y, Gabata T, Matsui O et al (2009) Enhancement patterns of pancreatic adenocarcinoma on conventional dynamic multi-detector row CT: correlation with angiogenesis and fibrosis. World J Gastroenterol 15:3114-3121
20. Yi CA, Lee KS, Kim EA et al (2004) Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. Radiology 233:191-199
21. Wang JH, Min PQ, Wang PJ et al (2006) Dynamic CT evaluation of tumor vascularity in renal cell carcinoma. Am J Roentgenol 186:1423-1430
22. Wang ZQ, Li JS, Lu GM, Zhang XH, Chen ZQ, Meng K (2003) Correlation of CT enhancement, tumor angiogenesis and pathologic grading of pancreatic carcinoma. World J Gastroenterol 9:2100-2104
23. Kwak BK, Shim HJ, Park ES et al (2001) Hepatocellular carcinoma: correlation between vascular endothelial growth factor level and degree of enhancement by multiphase contrast-enhanced computer tomography. Invest Radiol 36:487-492
24. Sahani DV, Holalkere NS, Mueller PR, Zhu AX (2007) Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue-initial experience. Radiology 243:736-743
25. Sahani DV, Kalva SP, Hamberg LM et al (2005) Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology 234:785-792
26. Ellika SK, Jain R, Patel SC et al (2007) Role of perfusion CT in glioma grading and comparison with conventional MR imaging features. Am J Neuroradiol 28:1981-1987
27. Li Y, Yang ZG, Chen TW, Chen HJ, Sun JY, Lu YR (2008) Peripheral lung carcinoma: correlation of angiogenesis and first-pass perfusion parameters of 64-detector row CT. Lung Cancer 61:44-53
28. Ma SH, Xu K, Xiao ZW et al (2007) Peripheral lung cancer: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and cyclin D1 expression. Clin Imaging 31:165-177
29. Jain RK, Padera TP (2003) Development. Lymphatics make the break. Science 299:209-210
30. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62
31. Chun YS, Vauthey JN, Boonsirikamchai P et al (2009) Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302:2338-2344
32. Jubb AM, Oates AJ, Holden S, Koeppen H (2006) Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 6:626-635
33. Willett CG, Boucher Y, di Tomaso E et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147
34. Jiang T, Kambadakone A, Kulkarni NM, Zhu AX, Sahani DV (2012) Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 47:11-17
35. Morgan B, Thomas AL, Drevs J et al (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955-3964
36. Hirashima Y, Yamada Y, Tateishi U et al (2012) Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer 130:2359-2365
37. Hahn OM, Yang C, Medved M et al (2008) Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26:4572-4578